FibroGenesis, a developer of fibroblast-based therapeutic solutions for unmet medical needs, has entered into a manufacturing agreement with iBiologics to supply its proprietary allogeneic fibroblast cells to support FibroGenesis’s growing chronic disease platform and ongoing clinical trials.
 
“We are extremely pleased to partner with iBiologics to manufacture our breakthrough fibroblasts,” said Pete O’Heeron, chief executive officer, FibroGenesis. “Our collaboration with iBiologics has produced the highest quality fibroblasts available and their adherence to GMP processes assures us of a reliable source for this unique cell line which will ultimately help patients suffering from chronic diseases.”
 
Francisco Silva, chief executive officer, iBiologics, said, “FibroGenesis has a unique and impressive platform technology and is positioned to secure its place as a premier provider of cell-based therapeutics and we look forward to being part of this process.”
 
iBiologics is a contract development and manufacturing organization (CDMO) for the development and manufacturing of autologous and allogeneic cell and gene therapy products.  It provides a combination of custom services to companies across all points of translational and clinical development.